INFLAMMATORY BOWEL DISEASE: APPROACH TO MANAGE FROM VARIOUS ASPECTS

PDF

Published: 2021-12-10

Page: 1360-1365


BARSHA PRIYADARSHINI

CPS, PURI, Odisha, India.

B. RAY *

Post Graduate Department, CPS, PURI, Odisha, India.

AMIYAKANTA MISHRA

Post Graduate Department, CPS, PURI, Odisha, India.

ASITKUMAR SARANGI

Post Graduate Department, CPS, PURI, Odisha, India.

PRIYANK PRIYADARSHINI

CPS, PURI, Odisha, India.

*Author to whom correspondence should be addressed.


Abstract

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Crohn's disease and ulcerative colitis are the principal types of inflammatory bowel disease. IBD has evolved into a global disease with great variations affecting not only the highly developed countries in North America and Europe but also the newly industrialized countries in Asia. In Europe, the incidence of UC is 24.3–505 per 100,000 person-years, and that of CD is 12.7–322 per 100,000 person-years. The Present review focus Different aspects of IBD and Various Management to counteract the Disease.

Keywords: Enteropathy, colitis, nanodrug, pathogenesis, corticosteroid


How to Cite

PRIYADARSHINI, B., RAY, B., MISHRA, A., SARANGI, A., & PRIYADARSHINI, P. (2021). INFLAMMATORY BOWEL DISEASE: APPROACH TO MANAGE FROM VARIOUS ASPECTS. Asian Journal of Advances in Research, 4(1), 1360–1365. Retrieved from https://jasianresearch.com/index.php/AJOAIR/article/view/21

Downloads

Download data is not yet available.

References

Talley NJ, Abreu MT, Achkar J, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am. J. Gastroenterol. 2011;106:S2–S25. [CrossRef]

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317. [CrossRef] [PubMed]

Osada T, Ohkusa T, Okayasu I, Yoshida T, Hirai S, Beppu K, Shibuya T, Sakamoto N, Kobayashi O, Nagahara A, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J. Gastroenterol. Hepatol. 2008;23: S262–S267. [CrossRef] [PubMed]

Keshteli AH, Madsen KL, Dieleman LA. Diet in the pathogenesis and management of ulcerative colitis: A review of randomized controlled dietary interventions. Nutrients. 2019;11:1498. [CrossRef]

Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010; 139:1816–1819. [CrossRef]

López-Serrano P, Pérez-Calle JL, Pérez-Fernández MT, Fernández-Font JM, de Miguel DB, Fernández-Rodríguez CM. Environmental risk factors in inflammatory bowel diseases. Investigating the hygiene hypothesis: A Spanish case–control study. Scand. J. Gastroenterol. 2010;45:1464–1471. [CrossRef]

Hisamatsu T, Inoue N, Yajima T, Izumiya M, Ichikawa H, Hibi T. Psychological aspects of inflammatory bowel disease. J. Gastroenterol. 2007;42:34–40. [CrossRef]

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. [CrossRef] [PubMed]

Klampfer L. Cytokines, Inflammation and Colon Cancer. Curr. Cancer Drug Targets 2011;11:451–464. [CrossRef] [PubMed]

Reddy D, Siegel CA, Sands BE, et al. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006;101:1569–1573.

Reniers DE, Howard JM. Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann Pharmacother. 2001;35:1214–1216.

Coco R, Plapied L, Pourcelle V, Jerome C, Brayden DJ, Schneider Y, Preat V. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. Int. J. Pharm. 2013;440:3–12. [CrossRef]

van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nature Reviews Rheumatology. 2013;9(3):164– 172.

Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Archivum Immunologiae et Therapiae Experimentalis. 2012;60(5):331–344.

Schellekens H. The immunogenicity of therapeutic proteins. Discovery Medicine. 2010;9:560–564

van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EMJ, Faber KN, Sluiter WJ, Kleibeuker J, Dijkstra G. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis. 2009;15:1199–1207. [CrossRef]

Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastian VP, Alvarez-Lobos MM, Bueno SM. Impact of cigarette smoking on the gastrointestinal tract inflammation: opposing effects in Crohn’s Disease and Ulcerative Colitis. Front. Immunol. 2018;9:74. [CrossRef]